Plain-English translation of NCT06372613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a protein found in blood called leucine-rich α 2-glycoprotein (LRG) to see if it can serve as a simple, noninvasive marker to tell whether ulcerative colitis is truly in remission. Right now, doctors have to do colonoscopies with tissue biopsies to confirm healing, which is invasive. If LRG levels in the blood can reliably predict remission, it could offer patients a less burdensome way to monitor their disease.
Ulcerative colitis patients currently need colonoscopies with biopsies to confirm their disease is healed, which is uncomfortable and costly. This trial aims to find out if a simple blood test could replace or reduce the need for these invasive procedures by identifying a reliable blood marker.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn to measure the protein LRG. Your doctors will monitor your symptoms and perform colonoscopies with tissue biopsies when they believe your ulcerative colitis may be in remission, regardless of your blood test results or how you feel. Researchers will then compare your blood LRG levels to the actual tissue healing seen on biopsy to determine if the blood test can reliably predict remission.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Japan
Enrollment target
~100 participants
Started
February 2024
Primary completion
December 2027
Age range
20 Years – 90 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Akia Horiuchi
Showa Inan General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.